You are here

Power vacuum, Alzheimer's trials fuelling Biogen takeover rumours

But analysts remain sceptical Merck & Co and Allergan will actually make an offer for the drugmaker

The experimental therapies Biogen is developing include treatments for Alzheimer's disease - a market with vast potential.


ON July 21, as Biogen chief executive officer George Scangos announced he would step down, he floated the idea that his company might buy rivals to cement its place near the top of the booming field of biotechnology. Today, Biogen looks more like prey than predator.


Market voices on: